Tubulin Modulators

• 

  Subject Areas on Research

  • A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. 
  • A cellular genome-wide association study reveals human variation in microtubule stability and a role in inflammatory cell death. 
  • A cut above the other caspases. 
  • A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer. 
  • Anti-tubulin drugs conjugated to anti-ErbB antibodies selectively radiosensitize. 
  • Antitumor agents. 139. Synthesis and biological evaluation of thiocolchicine analogs 5,6-dihydro-6(S)-(acyloxy)- and 5,6-dihydro-6(S)-[(aroyloxy)methyl]-1,2,3-trimethoxy-9-(methylthio)-8H- cyclohepta[a]naphthalen-8-ones as novel cytotoxic and antimitotic agents. 
  • Antitumor agents. 172. Synthesis and biological evaluation of novel deacetamidothiocolchicin-7-ols and ester analogs as antitubulin agents. 
  • Co-occurrence of idiopathic granulomatous hepatitis and primary biliary cirrhosis. 
  • DEPDC1/LET-99 participates in an evolutionarily conserved pathway for anti-tubulin drug-induced apoptosis. 
  • Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. 
  • Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. 
  • Important considerations for trials for peripheral arterial disease: Lessons learned from the paclitaxel mortality signal: A report on behalf of the registry assessment for peripheral interventional Devices (RAPID) Paclitaxel Pathways Program. 
  • Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program. 
  • Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. 
  • Mitotic phosphorylation of eukaryotic initiation factor 4G1 (eIF4G1) at Ser1232 by Cdk1:cyclin B inhibits eIF4A helicase complex binding with RNA. 
  • Novel chemotherapies in development for management of castration-resistant prostate cancer. 
  • The Cobalt chromium STent with Antiproliferative for Restenosis II (COSTAR II) trial study design: advancing the active-control evaluation of second-generation drug-eluting stents. 
  • The impact of familial Mediterranean fever on women's health.